ATH 25.0% 0.5¢ alterity therapeutics limited

From thestreet [The Lundbeck drug, idalopirdine, failed to...

  1. 5,826 Posts.
    lightbulb Created with Sketch. 143


    From thestreet


    [The Lundbeck drug, idalopirdine, failed to improve the cognition of mild to moderate Alzheimer's patients when added to donepezil, a current Alzheimer's medicine, Lundbeck said Thursday.]
    [The company, in its statement, said idalopirdine showed a "weak efficacy profile" in the phase III study, although the drug was safe and well tolerated.
    Idalopirdine belongs to a class of Alzheimer's drugs known as 5-HT6 antagonists.
    Axovant is developing a competing 5-HT6 antagonist, intepiridine, currently in a phase III study.
    Axovant shares tumbled 23% to $13.22 soon after the Lundbeck drug failure was announced.]
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $27.94K 6.050M

Buyers (Bids)

No. Vol. Price($)
46 57663299 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 56205001 43
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 20524121
Last updated 15.46pm 29/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.